AAAAAA

   
Results: 1-2 |
Results: 2
Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element
Authors: Tagat, JR McCombie, SW Steensma, RW Lin, SI Nazareno, DV Baroudy, B Vantuno, N Xu, S Liu, J
Citation: Jr. Tagat et al., Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element, BIOORG MED, 11(16), 2001, pp. 2143-2146
Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoro-methyl)phenyl]ethyl]-1-piperazinyl]-piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist
Authors: Tagat, JR Steensma, RW McCombie, SW Nazareno, DV Lin, SI Neustadt, BR Cox, K Xu, S Wojcik, L Murray, MG Vantuno, N Baroudy, BM Strizki, JM
Citation: Jr. Tagat et al., Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoro-methyl)phenyl]ethyl]-1-piperazinyl]-piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist, J MED CHEM, 44(21), 2001, pp. 3343-3346
Risultati: 1-2 |